Autoantibodies and Sjogren’s Syndrome in Multiple Sclerosis, a Reappraisal

Solomon, Andrew; Hills, William L.; Chen, Zunqiu; Rosenbaum, James T.; Bourdette, Dennis; Whitham, Ruth H.

doi:10.1371/journal.pone.0065385

Cited by 24 publications

(20 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding was much different from previous studies in MS that identified SSA/SSB [30] and the finding of SSA/SSB in this study was very similar to NMO [31]. Moreover, the incidences of BON and ION with SSA/SSB were similar to MS in previous studies [32]. SS was a systemic autoimmune disease that presents with sicca symptomatology of the main mucosal surfaces and gland inflammation, and often presented with other immunological diseases [33].…”

Section: Discussioncontrasting

confidence: 99%

Frequency of Autoantibodies and Connective Tissue Diseases in Chinese Patients with Optic Neuritis

Zhang

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

BackgroundOptic neuritis (ON) is often associated with other clinical or serological markers of connective tissue diseases (CTDs). To date, the effects of autoantibodies on ON are not clear.PurposeTo assess the prevalence, clinical patterns, and short outcomes of autoantibodies and Sjögren’s syndrome (SS) involvement in Chinese ON patients and evaluate the relationship between ON, including their subtypes, and autoantibodies.MethodsA total of 190 ON patients were divided into recurrent ON (RON), bilateral ON (BON), and isolated monocular ON (ION). Demographic, clinical, and serum autoantibodies data were compared between them with and without SS involvement. Serum was drawn for antinuclear antibody (ANA), extractable nuclear antigen antibodies (SSA/SSB), rheumatoid factor (RF), anticardiolipin antibodies (ACA), and anti-double-stranded DNA antibody (A-ds DNA), anticardiolipin antibody (ACLs), anti-β2-glycoprotein I (β2-GPI) and Aquaporin-4 antibodies (AQP4-Ab). Spectral-domain optical coherence tomography (SD-OCT) was used to evaluate the atrophy of the optic nerve.Results68 patients (35.79%) had abnormal autoantibodies, 26(13.68%) patients met diagnostic criteria for CTDs, including 15(7.89%) patients meeting the criteria for SS. Antibodies including SSA/SSB 23 (30.26%) (p1 and p 2<0.001) and AQP4–Ab10 (13.16%) (p1 = 0.044, p2 = 0.01) were significantly different in patients in the RON group when compared with those in the BON (P1 = RON VS ION) and ION (p2 = RON VS ION) groups. SS was more common in RON patients (p1 = 0.04, p2 = 0.028). There was no significant difference between SSA/SSB positive and negative patients in disease characteristics or severity. Similar results were obtained when SS was diagnosed in SSA/SSB positive patients.ConclusionRON and BON were more likely associated with abnormal autoantibodies; furthermore, AQP4 antibody, SSA/SSB and SS were more common in the RON patients. AQP4 antibodydetermination is crucial in RON patients who will develop NMO. However, when compared with other autoantibodies, SSA/SSB detected in patients was not significantly associated with disease characteristics or severity.

show abstract

Section: Discussioncontrasting

confidence: 99%

Frequency of Autoantibodies and Connective Tissue Diseases in Chinese Patients with Optic Neuritis

Zhang

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Coexisting autoimmune disorders, as well as sero-autoantibodies, were significantly more common in seropositive patients; SS and SLE were the most common CTDs and SSA and SSB were the most common autoantibodies in these patients. These findings are similar to previous studies which found that NMO could coexist with CTDs [43], particularly SS [44]; however, this association is rare in MS [45,46], as the prevalence of MS with SS ranges from 0 to 3.3 % [47]. Since AQP-4 Ab is a sensitive bio- CSF findings in NMO have been found to differ significantly from those of classical MS [48,49].…”

Section: Discussionsupporting

confidence: 90%

Features of anti-aquaporin 4 antibody-seropositive Chinese patients with neuromyelitis optica spectrum optic neuritis

Wang

et al. 2015

J Neurol

View full text Add to dashboard Cite

The detection of anti-aquaporin-4 autoantibody (AQP-4 Ab) is crucial to detect patients who will develop neuromyelitis optica (NMO); however, there are few studies on the AQP-4 Ab serostatus of patients with neuromyelitis optica spectrum ON. We analyzed the clinical and paraclinical features of neuromyelitis optica spectrum ON patients in China according to the patients' AQP4-Ab serostatus. 125 patients with recurrent and bilateral ON with simultaneous attacks were divided into AQP-4 Ab-seropositive and -seronegative groups. Demographic, clinical, serum autoantibody data, connective tissue disorders (CTDs), visual performance were compared. A Visual Acuity (VA) of less than 0.1 during acute ON attacks occurred more frequently in the seropositive group (p = 0.023); however, there was not a significant difference between groups on VA recovery after the first attack. The seropositive group experienced the worst outcome during the last attack (p = 0.017). Other co-existing autoimmunity antibodies (p < 0.001) and CTDs (p < 0.001) were more prevalent in seropositive patients. There were no significant differences on VA recovery and RNFLT combined with other autoantibodies or CTDs. The two groups did not differ significantly with regard to time to relapse, annualized relapse rates, time of diagnosis NMO, or RNFL. There were no significant differences on VA recovery and RNFLT combined with other autoantibodies or CTDs. RNFLT was thinner in NMO seropositive patients. Although AQP-4 Ab expression predicted poor visual outcome, positive patients were usually associated with mild symptoms at first onset. Anti-SSA/SSB antibody or Sjögren syndrome may be associated with AQP-4 Ab in neuromyelitis optica spectrum ON.

show abstract

“…Besides, while the prevalence of Sjögren's syndrome in society is between 1% and 5%, this rate was found to be 0.9% in the present study (15). These results contradict the previous studies, which have demonstrated that Sjögren's syndrome is more frequent in MS patients, but they are similar to the ratios found out in the study carried out by Solomon et al on MS patients (14).…”

Section: Discussioncontrasting

confidence: 99%

Evaluation of autoantibody positive in multiple sclerosis patients

Gökçe¹,

Çiğdem²

2019

Cumhuriyet Medical Journal

View full text Add to dashboard Cite

Multiple sclerosis (MS) is the most common autoimmune disease of the central nervous system in which impaired immune activation is involved. It is known that other autoimmune diseases are seen more frequently in MS patients. Many rheumatologic diseases could cause neurologic disorders that mimic MS. Our aim in this study is to determine the rates of autoantibody positivity and the clinical significance of these positivity rates in patients with MS. Method: 110 patients who were followed up with MS diagnosis in our clinic between 2008 and 2018 were retrospectively evaluated for autoimmune disease biomarkers. The diagnosis of MS was confirmed using both 2005 and 2010 Revised Mc Donald Criteria. Results: The ANA (antinuclear antibody) positivity rate in our patients was 10.9%, the ANA profile positivity was 9.1%. Anti-ds DNA (double stranded deoxyribonucleic acid) positivity rate was 1.8%, anti-cardiolipin Ig (immunglobulin) G and Ig M were 0.9% positive. Anti-microsomal antibody positivity was 11.8% while antithyroglobulin antibody was positively 13.6%. The value of complement 3 (C3) was found to be 92.7% normal and 4.5% higher and 2.7% lower, respectively. The C4 values were 98.2% normal, while they were 11.8% higher than normal. Six patients had six different diseases in which ethiopathogenesis the role of autoimmunity was also revealed (ankylosing spondylitis, psoriasis, systemic lupus erythematosus, morfea, ptriyazis, Sjögren's syndrome). Conclusions: Although some autoantibody positivities in MS patients are more frequent than healthy controls, these positivities are not usually associated with systemic rheumatologic disease and haven't clinical significance. Therefore, the evaluation of autoantibodies in each MS patient does not seem cost effective. So, the MS patients whose autoantibody levels are to be measured should be well selected before the evaluation the patients' medical history and complaints should be taken into consideration.

show abstract

Autoantibodies and Sjogren’s Syndrome in Multiple Sclerosis, a Reappraisal

Cited by 24 publications

References 39 publications

Frequency of Autoantibodies and Connective Tissue Diseases in Chinese Patients with Optic Neuritis

Frequency of Autoantibodies and Connective Tissue Diseases in Chinese Patients with Optic Neuritis

Features of anti-aquaporin 4 antibody-seropositive Chinese patients with neuromyelitis optica spectrum optic neuritis

Evaluation of autoantibody positive in multiple sclerosis patients

Contact Info

Product

Resources

About